Colorectal Cancer Diagnostics Market Scope 2028 - Navigating the Competitive World

Colorectal cancer diagnostics refers to the tools, kits and test performed on an individual to diagnose colorectal cancer in an individual. This involves series of non-invasive and invasive test to confirm the cancer and its stage based on that treatment will be provided to the patient.

Medtronic Plc and Boston Scientific Corporation – Notable Market Players in Colorectal Cancer Diagnostics Market

Key driving factors include the factors driving the colorectal cancer diagnostics market growth are increasing prevalence of colorectal cancer and launches of new products. However, the low accuracy of screening based on fecal immunochemical tests (FITs)hinders the colorectal cancer diagnostics market growth.

The colorectal cancer diagnostics market is majorly comprised of top players involving Medtronic Plc, Illumina Inc, Clinical Genomics Technologies Pty Ltd, EDP Biotech Corp, Epigenomics AG F. Hoffmann-La Roche Ltd, Quest Diagnostics Inc, Novigenix SA, Siemens Healthineers AG, Bruker Corp, and Eiken Chemical Co., Ltd. among others.

The companies listed above are implementing various strategies such as product launches, acquisitions, mergers, and partnerships, which have resulted in the company’s growth and, in turn, have brought about various changes in the worldwide market. Additionally, the companies have adopted several organic strategies for accelerating their growth and improving their market position.

Below is the list of the growth strategies done by the players operating in the colorectal cancer diagnostics market:

Year	News
March 2023	Sengkang General Hospital collaborate with Medtronic promote AI-assisted colonoscopies. The two organizations have signed a memorandum of understanding to promote AI-assisted colonoscopy for colorectal cancer screening.
August 2021	Illumina Acquired GRAIL to Accelerate Patient Access to Life-Saving Multi-Cancer Early-Detection Test. GRAIL’s Galleri blood test detects 50 different cancers before they are symptomatic. Illumina’s acquisition of GRAIL will accelerate access and adoption of this life-saving test worldwide.
January 2020	Illumina, Roche Launched NGS-Based Cancer Diagnostics Partnership. Illumina and Roche have signed a 15-year, non-exclusive collaboration agreement designed to realize next-generation sequencing’s potential to transform cancer risk prediction, detection, diagnosis, treatment, and monitoring.
April 2020	Clinical Genomics Expands Strategic Relationship with Quest Diagnostics for Innovative First-Line Colorectal Cancer Screening Blood Test. The alliance also expands the company’s commercialization rights for hte Trident Program and COLVERA for CRC monitoring outside the US, Mexico, UK, and India.